Navigation Links
Bayer HealthCare's Cotavance® Drug Eluting Balloon With Paccocath® Technology Reduced Five-Year Target Lesion Revascularization Rates by 59 Percent in PAD Patients Compared to Those Treated With Uncoated Balloon
Date:11/10/2011

WARRENDALE, Pa., Nov. 10, 2011 /PRNewswire/ -- Bayer HealthCare's affiliate MEDRAD, Inc. today announced that five-year data from the THUNDER trial* demonstrated a 59 percent relative reduction in target lesion revascularization (TLR) rates in popliteal arteries of patients with peripheral arterial disease (PAD) treated with the Cotavance® drug eluting balloon with Paccocath® technology compared to standard balloon angioplasty (POBA). Additionally, for patients requiring TLR, the average time to revascularization before TLR was extended by 448 days in patients treated with the Cotavance catheter, which is available in Europe, but not yet approved in the U.S. MEDRAD is currently moving forward with the Investigational Device Exemption (IDE) process as one of the steps in gaining FDA approval for Cotavance product in the United States.

The data were presented at the 2011 Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation, in San Francisco as part of a TCT-sponsored symposium titled, "Drug-Coated Balloons: Clinical Data and Applications."

"These data with Bayer HealthCare's Paccocath technology represent the only five-year clinical TLR outcomes in comparison to standard balloons," said Prof. Dr. med. Gunnar Tepe of Klinikum Rosenheim in Rosenheim, Germany, principal investigator of THUNDER. "The results demonstrate clear long-term benefits for patients with the Cotavance paclitaxel eluting balloon for reducing the number of TLR procedures and extending the time before a revascularization might be needed in PAD patients." Dr. med. Thomas Zeller of Herz-Zentrum, Bad Krozingen, Germany, who presented the data at the TCT symposium, added, "Beginning as early as the first year and continuing through year five, a consistent 30 to 40 percent improvement was seen with the Cotavance catheter in avoiding TLR. TCT was an excellent venue to share these ground-breaking data."

D
'/>"/>

SOURCE Bayer HealthCare-MEDRAD, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Bayer Broadens Its Manufacturing Basis for Biopharmaceuticals in Tobacco Plants
2. GeneGo Renews Its Agreement With Bayer Schering Pharma AG for Another Three Years
3. Micromet Enters Into Agreement for Solid Tumor BiTE Antibody with Bayer Schering Pharma AG
4. Stemedica Announces the Appointment of Dr. Michael Bayer as Director, Medical Services
5. Bayer CropScience Donates $1.1 Million to United Fresh Research & Education Foundation to Create the Center for Global Produce Sustainability
6. Bayer and Onyx Announce Nexavar Data Presentations at 45th American Society of Clinical Oncology Annual Meeting
7. Onyx Pharmaceuticals Files Complaint Against Bayer Corporation
8. Neptune Products to be commercialized by BAYER HealthCare
9. DuPont and Bayer CropScience Expand Collaboration With Broad License Agreements
10. Bayers CONTOUR and Bayers BREEZE2 Blood Glucose Monitoring Systems Do Not Use Problematic GDH-PQQ Technology
11. Bayer CropScience Announces Investment of $25 Million for Institute Site
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... Aug. 27, 2014 Guggenheim Securities, the investment ... announced the hiring of veteran equity analyst Charles "Tony" ... Mr. Butler will focus on the biotech/biopharma sector. ... wealth of experience and a broad network of relationships ... Managing Director and Head of Equities at Guggenheim Securities. ...
(Date:8/27/2014)... (PRWEB) August 27, 2014 Flagship Biosciences ... services to the pharmaceutical and medical device industries, ... The fast growing company has consolidated its histology ... and Boulder to Westminster, CO, just north of Denver. ... Lab, 7575 W. 103rd Ave., Suite 100, Westminster, CO ...
(Date:8/27/2014)... Research and Markets  has announced the addition of ... Report 2014" report to their offering. ... Report 2014 is a professional and in-depth study on ... spectrometer industry. The report provides a basic ... industry chain structure. The isotope ratio mass spectrometer market ...
(Date:8/27/2014)... MONMOUTH JUNCTION, N.J. , Aug. 27, 2014 /PRNewswire/ ... developing innovative drug delivery technologies, today announced that it ... New Jersey Business & Industry Association,s 2014 Awards ... Finalists were selected by an independent panel of judges ... member company volunteers. Award winners will be honored at ...
Breaking Biology Technology:Guggenheim Securities Hires Analyst Charles "Tony" Butler to Expand Healthcare Coverage 2Flagship Biosciences Announces Relocation and Expansion 2Global Stable Isotope Ratio Mass Spectrometer Industry Report 2014 2Tris Pharma Selected as an award winner in the New Jersey Business & Industry Association's 2014 Awards for Excellence 2
... 7 Interleukin Genetics,Inc. (Amex: ILI ), a ... genetic tests for sale to the,emerging personalized health market, ... 2007. The Company recorded revenue of $2.6 million ... for third quarter ended September 30,2006, a 92% increase. ...
... Symbol: MS, EDMONTON, Nov. 7 /PRNewswire-FirstCall/ - ... the treatment of multiple sclerosis (MS), today,announced that ... the,Company,s phase II MINDSET-01 trial of MBP8298 in ... and recommended that,the trial continue as per the ...
... Transgenomic Inc. (OTC,Bulletin Board: TBIO) announces the following Webcast: What: ... Conference Call, When: ... http://www.transgenomic.com/events.asp?id=6 , How: Live ... address above., ...
Cached Biology Technology:Interleukin Genetics, Inc. Reports Third Quarter 2007 Financial Results 2Interleukin Genetics, Inc. Reports Third Quarter 2007 Financial Results 3Interleukin Genetics, Inc. Reports Third Quarter 2007 Financial Results 4Interleukin Genetics, Inc. Reports Third Quarter 2007 Financial Results 5Interleukin Genetics, Inc. Reports Third Quarter 2007 Financial Results 6BioMS Medical's relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board 2Webcast Alert: Transgenomic Inc. Announces Third Quarter 2007 Earnings Release Conference Call Webcast 2
(Date:8/28/2014)... alert the world to Global Warming, has called for ... underground. He says that Carbon Capture, combined with limits ... avoid global warming getting out of control over the ... made the call during his presentation to the International ... meeting to discuss Carbon Capture and Storage. , ...
(Date:8/27/2014)... The mechanical force that a single fungal cell or ... small, but it plays a heavy role in setting up ... fact, it may not be too much of a stretch ... without the ability to respond to the touch of beneficial ... a professor of agronomy at the University of Wisconsin-Madison. ...
(Date:8/27/2014)... Reportlinker.com announces that a new market ... Law Enforcement Biometrics Market in North America ... About Biometrics Biometrics is a technology that ... their physical or behavioral patterns. It involves the ... as fingerprints, face recognition, DNA, palm print, hand ...
Breaking Biology News(10 mins):Global warming pioneer calls for CO2 to be taken from atmosphere and stored underground 2A touching story: The ancient conversation between plants, fungi and bacteria 2A touching story: The ancient conversation between plants, fungi and bacteria 3Law Enforcement Biometrics Market in North America 2014-2018 2Law Enforcement Biometrics Market in North America 2014-2018 3Law Enforcement Biometrics Market in North America 2014-2018 4Law Enforcement Biometrics Market in North America 2014-2018 5
... alAbsi, Ph.D., and a team of national collaborators have ... National Institutes of Health (NIH) for their research, AutoSense: ... alAbsi is a professor and founding director of Duluth ... SchoolDuluth Campus. , The project is among the first ...
... UC Davis Institute of Transportation Studies (ITS-Davis) will,co-sponsor ... Research to Practice" next month in Berkeley. ... local government,officials, private industry leaders, consultants and advisers, ... include: Innovative highway and ...
... million gift to the University of Michigan Health System is ... a mission of supporting fundamental research to advance the understanding ... of human diseases. The A. Alfred Taubman Medical Research ... for the retail pioneer whose funding and vision led to ...
Cached Biology News:Mustafa al'Absi Ph.D. and national team awarded major NIH grant 2$22 million gift from Alfred Taubman launches new biomedical research institute 2$22 million gift from Alfred Taubman launches new biomedical research institute 3$22 million gift from Alfred Taubman launches new biomedical research institute 4
Mouse monoclonal antibody to CDC2L5 - cell division cycle 2-like 5 (cholinesterase-related cell division controller)...
...
Our Histology, Immunohistochemistry and tissue arrays services include samples processing, different type of staning, histollogical stains, image analysis, tissue arrays, immunohistochemistry, etc....
Mouse monoclonal antibody to PDK2 - pyruvate dehydrogenase kinase, isoenzyme 2...
Biology Products: